恒瑞醫藥(600276.SH):擬推2024年員工持股計劃
格隆匯9月8日丨恒瑞醫藥(600276.SH)公佈2024年員工持股計劃,本員工持股計劃的股票來源為公司回購專用證券賬户中已回購的公司股份,員工擬受讓公司回購股份的數量不超過1220萬股(含預留份額),約佔員工持股計劃草案公吿日公司股本總額的0.19%。本員工持股計劃最終持有標的股票的數量以實際執行情況為準,公司將根據規定及時履行信息披露義務。本員工持股計劃設立後,擬通過非交易過户等形式受讓公司回購專用證券賬户中持有的股份,受讓價格為21.20元/股;本員工持股計劃的參加對象總人數不超過1203人(不含預留份額),具體人數根據實際情況而定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.